SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Merck & Co., Inc. Release: North American Phase III Trial With Grass Allergy Immunotherapy Tablet Meets Primary Endpoint, FDA Filing Remains Planned for 2013